This study is in progress, not accepting new patients
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Santa Monica, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jonathan Goldman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Jonathan Goldman
Hs Clinical Professor, Medicine. Authored (or co-authored) 108 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- To obtain contact information for a study center near you, click here.
- ID
- NCT03915951
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 98 people participating
- Last Updated